Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Recurrent or Metastatic Endometrial Cancer
NCT01935934Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2013
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of cabozantinib in endometrial cancer (EC), sponsored by National Cancer Institute. Started May 2013; status: completed.
02
Drugs
cabozantinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT01935934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01935934.